Reaction

Ingrowing Nail reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,328 reports · 62 co-occurring drugs

As of the last recalculation, Ingrowing Nail appears in 2,328 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is LAPATINIB (PRR 16.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Lapatinib	29	16.9	16.9
Octreotide Acetate	51	15.2	15.2
Chlorhexidine Gluconate	14	13.8	13.8
Gefitinib	12	11.9	12.0
Esomeprazole Magnesium Capsule, Delayed Release	18	11.2	11.2
Esomeprazole Magnesium Delayed Release Capsules	18	11.2	11.2
Esomeprazole Magnesium Dihydrate	18	11.1	11.1
Cephalexin	26	10.9	10.9
Osimertinib	35	9.9	9.9
Docusate Sodium 100Mg	25	9.4	9.4
Mupirocin	14	9.3	9.3
Mupirocin Calcium	14	9.2	9.2
Ibrutinib	78	8.9	8.9
Hydrocortisone Sodium Succinate	9	8.6	8.6
Rosuvastatin Calcium	26	8.3	8.3
Sunitinib Malate	36	8.3	8.3
Psyllium Husk	9	8.2	8.2
Tolterodine Tartrate	8	8.0	8.0
Isotretinoin	43	7.9	7.9
Candesartan Cilexetil	23	7.9	7.9
Diphenoxylate Hydrochloride And Atropine Sulfate	12	7.9	7.9
Lidicaine	41	7.6	7.6
Burn Relief	41	7.6	7.6
Lidocaine Hydrochloride And Epinephrine	41	7.6	7.6
Lidocaine, Menthol	41	7.5	7.5
Everolimus	40	7.1	7.1
Biotin	24	6.9	6.9
Lidocaine	44	6.9	6.9
Lidocaine 4%	41	6.8	6.8
Infliximab-Dyyb	22	6.8	6.8
Trametinib	18	6.7	6.7
Olmesartan Medoxomil	26	6.5	6.5
Buspirone Hydrochloride	8	6.5	6.5
Erlotinib	7	6.5	6.5
Extended Phenytoin Sodium	12	6.4	6.4
Panitumumab	11	6.3	6.3
Exemestane	15	6.3	6.3
Terazosin Hydrochloride	6	6.0	6.0
Adrenalinum	27	5.9	5.9
Erlotinib Hydrochloride	8	5.7	5.7
Capecitabine	57	5.7	5.7
Raloxifene Hydrochloride	9	5.5	5.5
Prochlorperazine	17	5.5	5.5
Emicizumab	7	5.1	5.1
Umeclidinium	5	5.0	5.0
Desoximetasone	10	4.7	4.7
Niraparib	11	4.4	4.4
Miconazole Nitrate	4	4.1	4.1
Dabrafenib	9	3.8	3.8
Armodafinil	9	3.8	3.8
Cabozantinib	20	3.7	3.7
Avapritinib	5	3.7	3.7
Risankizumab-Rzaa	28	3.1	3.1
Alpelisib	3	3.1	3.1
Canagliflozin	9	2.7	2.7
Etanercept	172	2.7	2.7
Abiraterone	4	2.6	2.6
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	2.6	2.6
Ixazomib	8	2.5	2.5
Axitinib	5	2.3	2.3
Ixekizumab	9	2.2	2.2
Pomalidomide	15	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.